Sinopharm Group (1099) Q3 2024 earnings summary

Executive summary

• For the nine months ended 30 September 2024, Sinopharm Group reported consolidated financial results under PRC GAAP, with both group and company-level statements disclosed.

Financial highlights

• Group total operating revenue was RMB 442.4 billion, down from RMB 445.9 billion year-over-year.

• Net profit attributable to equity holders of the parent was RMB 5.28 billion, compared to RMB 6.10 billion in the prior year period.

• Basic and diluted EPS were RMB 1.69, down from RMB 1.96 year-over-year.

• Company-level net profit was RMB 1.57 billion, down from RMB 2.51 billion year-over-year.

• Cash and cash equivalents at group level decreased to RMB 36.0 billion from RMB 63.8 billion at the start of the period.

Segment performance

• Operating profit for the group was RMB 10.84 billion, down from RMB 13.05 billion year-over-year.

• Minority interest in net profit was RMB 3.11 billion, compared to RMB 3.97 billion in the prior year period.